Call Us +91 0416 2282352 Email us haemat@cmcvellore.ac.in

Faculty

Dr. Alok Srivastava

Dr. Alok Srivastava, MD, FRACP, FRCPA, FRCP

Professor

An alumnus of CMC, Vellore, Dr. Alok Srivastava has helped build the comprehensive adult and pediatric haematology service and teaching programs at this institution over the last three decades. He is a founder teacher for the DM haematology program in India. His research interests have been in hematopoietic stem cell transplantation (HSCT) and hemostasis disorders. Over the last 12 years, he has been responsible for establishing the Centre for Stem Cell Research, Vellore as a translational unit of the Institute of Stem Cell Science and Regenerative Medicine as a collaboration between this institute and CMC, Vellore with the Department of Biotechnology, Government of India. The focus of his current research is the development of gene therapy for hereditary hematological disorders with several international collaborations. He is also working with several colleagues in different departments of the CMC, Vellore to establish the first large comprehensive control program for the major haemoglobin disorders in India in the collaboration the state government in Odisha.

His research interests have been in hematopoietic stem cell transplantation (HSCT) and hemostasis disorders. Apart from the building the largest HSCT service in the country, his particular research interest was in improving outcomes of HSCT for thalassemia major by evaluating the pharmacokinetics and pharmacogenetics of drugs used for conditioning. He has been instrumental in establishing the Indian Stem Cell Transplant registry 15 years ago and continues to coordinates its activities. Over the last 12 years, he has been responsible for establishing the Centre for Stem Cell Research, Vellore as a translational unit of the Institute of Stem Cell Science and Regenerative Medicine as a collaboration between these two institutes and the Department of Biotechnology, Government of India. At CSCR, the focus is on developing various novel therapies towards for regenerative medicine. The focus of current research is the development of gene therapy for hereditary hematological disorders such as the major haemoglobin disorders - thalassemia and sickle cell disease with the help of several major international collaborations to bring that technology to the country. In parallel, he is also working with several colleagues in different departments of the CMC, Vellore to establish the first large comprehensive control program for the major haemoglobin disorders in India in the collaboration the state government in Odisha. http://www.cscr.in/dr-alok-srivastava/

In the field of haemostasis, over the last two decades, Dr. Srivastava has developed CMC, Vellore into a centre providing one of the most comprehensive services for patients with hereditary bleeding disorders in the world extending from the full range of clinical services from multidisciplinary clinical management including surgeries to genetic diagnosis for carrier detection and pre-natal detection of these diseases. His group has evaluated the genetics of one of the largest cohorts of such patients in the world. This was particularly necessary given the high prevalence of these conditions in Southern India with a high rate of consanguineous marriages resulting in large numbers of patients with these serious hereditary recessive disorders. It is also the centre which trains the largest number of people every year in the management of patients with bleeding disorders. More than 100 publications have resulted from the research in this field. http://www.cmchaematology.org/dr-alok-srivastava.php Current effort is also on developing gene therapy as a cure for these diseases particularly severe haemophilia with both adeno associated viral vectors as well as lenti viral vectors. ​

S.No. Project Title Duration
(Year) 		Funding Agency Starting Date

Current Projects
1 Novel Approaches to Hematological Disease (NAHD)

(i.) Gene Therapy for hematological diseases

(ii.) Applications of iPSC technology - Haplobanking and Disease modeling

(iii.) Establishing a model for control of thalassemia and sickle cell disease in India		 5 Department of Biotechnolo​gy (DBT), Government of India.
 Dec 2015

Completed Projects
1 Low dose prophylaxis in hemophilia – A multicenter international study in Developing countries 3 Bayer Hemophilia Awards Program, USA 2012
2 Assessment of an Anti-TFPI Aptamer in correcting the abnormal haemostasis of blood from patients with haemophilia and evaluation of its concentration - effect relationship. [Principal Investigator] 1 Archemix Corporation, USA 2010
3 Program support for Molecular Haematology – 7 projects Govt. of India [Co-Team Leader] 5 Department of Biotechnology
Govt. of India		 2009
4 Novel Molecular Mechanisms leading to a haemophilia “A” phenotype 2 Bayer Health Care-Hemophilia Awards Program, USA 2009
5 Centre for Stem Cell Research-A CMC – DBT Collaboration [Project Coordinator] 5 Department of Biotechnology
Govt. of India		 2006
6 An open label, single arm study to evaluate the efficacy and safety of
Rituximab in CD 20+ve Diffuse large
B cell lymphoma along with CHOP
Chemotherapy [Principal Investigator]		 4 Dr. Reddy’s Laboratory 2006
7 Evaluation of adult stem cells (Haematopoietic, Mesenchymal, Gastrointestinal epithelial):
Biology and potential applications In tissue regeneration, immune-modulation and as vehicles for gene therapy. [Program Coordinator]		 3 Department of Biotechnology
Govt. of India		 2005
8 Musculo-skeletal function in hemophilia in developing countries – First international multi-center study [Principal Investigator] 5 Bayer Health Care,
Hemophilia Awards Program, USA		 2003
9 Role of minor histocompatiblity system in the clinical outcome of familial bone marrow transplanation for thalassaemia major. [Principal Investigator-India] 2 ICMR-INSERM
Govts. of India and France		 2003
10 Haematopoietic stem cells: Establishing technology for collection, isolation, purification and expansion. [Principal Investigator] 3 Department of Biotechnology,
Govt. of India		 2002
11 Pharmacogenetics of Busulfan and Cyclophophamide [Principal Investigator] 3 CEFIPRA
(Indo-French)		 2001
12 Establishing a centre for genetic diagnosis of haemat. diseases (thalassaemia, haem-mophilia, Glanzmann thrombasthenia, leukaemias) [Joint Investigator] 6 Department of Biotechnology,
Govt. of India		 1999
13 A randomized trial of two schedules of subcutaneous HBV vaccination in patients with acute leukaemia [Co- Investigator] 2 Fluid Research,
CMC Hospital &Fulford (India) Ltd		 April, 1999
14 Evaluation of low dose FEIBA for haemostasis during surgery USA for patients with haemophilia and high titre inhibitors [Principal Investigator] 2 Baxter Healthcare,
USA		 Mar, 1999
15 Evaluation of low-dose continuous infusion of factor concentrates for
major surgery in severe haemophilia. [Principal Investigator]		 2
2		 Bayer Corp, USA
I.S.I spa, Italy
(Plasma derived factors)		 Jan, 1999
Jun, 1999
16 Arsenic trioxide for the treatment of APML
[Co-Investigator]		 1 Fluid Research,
CMC Hospital		 Jan, 1998
17 Joint study on Glanzmann thrombasthenia in India – Clinical, laboratory and genetic aspects [PrincipalInvestigator- India] 2 As above & NIH, USA (B.Coller)
MOH, Israel
(U.Seligsohn)		 Sept, 1997
18 Evaluation of amifostine for the prevention of cyclophosphamide induced haemorrhagic cystitis [Principal Investigator] 2 Fulford (India) Ltd Jan, 1997
19 Thalassaemias in the Indian sub-continent – Clinical management and prevention
[Co-Investigator]		 2 INSERM, France Aug,1995
20 BMT for thalassaemia in India – Setting up of an Advanced centre at CMC Hospital, Vellore
[Co-Investigator]		 5 ICMR,
Govt. of India		 Jan,1994
  • Mahabal GD, George L, Peter D, Bindra M, Thomas M, Srivastava A, Mathews V, George B, Pulimood SA. Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study. Clin Exp Dermatol. 2019 Mar;44(2):161-168.
  • Gouw SC, Timmer MA, Srivastava A, de Kleijn P, Hilliard P, Peters M, Blanchette V, Fischer K. Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia-specific instruments. Haemophilia. 2019 Jan;25(1):e1-e10.
  • Korula A, Devasia AJ, Fouzia NA, Nisham PN, Kulkarni U, Lakshmi KM, Abraham A, Srivastava A, Mathews V, George B. Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors. Indian J Hematol Blood Transfus. 2019 Jan;35(1):43-49.
  • David S, Nair SC, Singh GS, Alex AA, Ganesan S, Palani HK, Balasundaram N, Lakshmi KM, Joshi A, Kannan S, Korula A, Nambiatheyil Aboobacker F, Abraham A, George B, Apte SJ, Srivastava A, Mathews V. Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. Haemophilia. 2019 Jan;25(1):67-74.
  • Kuprash AD, Shibeko AM, Vijay R, Nair SC, Srivastava A, Ataullakhanov FI, Panteleev MA, Balandina AN. Sensitivity and Robustness of Spatially Dependent Thrombin Generation and Fibrin Clot Propagation. Biophys J. 2018 Dec 18;115(12):2461-2473.
  • Kulkarni U, Devasia AJ, Korula A, Fouzia NA, Nisham PN, Samoon YJ, Lakshmi KM, Abraham A, Srivastava A, Mathews V, George B. Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biol Blood Marrow Transplant. 2018 Dec;24(12):e31-e35.
  • Elayaperumal S, Fouzia NA, Biswas A, Nair SC, Viswabandya A, George B, Abraham A, Oldenburg J, Edison ES, Srivastava A. Type-3 von Willebrand disease in India-Clinical spectrum and molecular profile. Haemophilia. 2018 Nov;24(6):930-940.
  • Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, Abraham A, Viswabandya A, Mathews V, George B, Srivastava A, Balasubramanian P. Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 Nov;53(11):1490.
  • Doering CB, Denning G, Shields JE, Fine EJ, Parker ET, Srivastava A, Lollar P, Spencer HT. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A. Hum Gene Ther. 2018 Oct;29(10):1183-1201.
  • Devasia AJ, Mammen S, Korula A, Abraham A, Fouzia NA, Lakshmi KM, Abraham AM, Srivastava A, Mathews V, George B. A Low Incidence of Cytomegalo Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation Despite a High Seroprevalence. Indian J Hematol Blood Transfus. 2018 Oct;34(4):636-642.
  • Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, Bennaceur Griscelli A, Chandra A, Elwood N, Girard M, Kawamata S, Hanatani T, Latsis T, Lin S, Ludwig TE, Malygina T, Mack A, Mountford JC, Noggle S, Pereira LV, Price J, Sheldon M, Srivastava A, Stachelscheid H, Velayudhan SR, Ward NJ, Turner ML, Barry J, Song J. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018 Oct;13(7):859-866.
  • Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, El Haddad A, Hashmi SK. Challenges in managing graft-versus-host disease in developing countries: a perspective. Bone Marrow Transplant. 2018 Sep 20.
  • Jain P, Korula A, Deshpande P, Pn N, Abu Alex A, Abraham A, Srivastava A, Janet NB, Lakshmi KM, Balasubramanian P, George B, Mathews V. Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country. J Glob Oncol. 2018 Sep;(4):1-12.
  • Haxaire C, Hakobyan N, Pannellini T, Carballo C, McIlwain D, Mak TW, Rodeo S, Acharya S, Li D, Szymonifka J, Song X, Monette S, Srivastava A, Salmon JE, Blobel CP. Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNFα pathway. Blood. 2018 Sep 6;132(10):1064-1074.
  • Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Na F, Abraham A, Viswabandya A, George B, Mathews V, Srivastava A, Balasubramanian P. Pharmacokinetics and pharmacodynamics of Treosulfan in patients with thalassemia major undergoing allogeneic hematopoietic stem celltransplantation.Clin Pharmacol Ther. 2018 Sep;104(3):575-583.
  • Dunkley S, Lam JCM, John MJ, Wong RSM, Tran H, Yang R, Nair SC, Shima M, Street A, Srivastava A. Principles of haemophilia care: The Asia Pacific perspective. Response. Haemophilia. 2018 Jul;24(4):e243-e244.
  • Duraisamy SK, Mammen S, Lakshminarayan SKR, Verghese S, Moorthy M, George B, Kannangai R, Varghese S, Srivastava A, Abraham AM. Performance of an in-house real-time PCR assay for detecting Cytomegalovirus infection among transplant patients from a tertiary care centre. Indian J Med Microbiol. 2018 Apr-Jun;36(2):241-246.
  • Alex AA, Ganesan S, Palani HK, Balasundaram N, David S, Lakshmi KM, Kulkarni UP, Nisham PN, Korula A, Devasia AJ, Janet NB, Abraham A, Srivastava A, George B, Padua RA, Chomienne C, Balasubramanian P, Mathews V. Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. Front Immunol. 2018 Jun 14;9:1357.
  • Nemani S, Korula A, Agrawal B, Kavitha ML, Manipadam MT, Sigamani E, George B, Srivastava A, Viswabandya A, Mathews V. Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. Indian J Med Res. 2018 May;147(5):464-470.
  • Mahlangu J, Cerquiera M, Srivastava A. Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May;24 Suppl 6:15-21.
  • Manian KV, Bharathan SP, Maddali M, Srivastava VM, Srivastava A, Velayudhan SR. Generation of an integration-free iPSC line (CSCRi005-A) from erythroid progenitor cells of a healthy Indian male individual. Stem Cell Res. 2018 May;29:148-151
  • Dunkley S, Lam JCM, John MJ, Wong RSM, Tran H, Yang R, Nair SC, Shima M, Street A, Srivastava A; Asia-Pacific Haemophilia Working Group (APHWG). Principles of haemophilia care: The Asia-Pacific perspective. Haemophilia. 2018 May;24(3):366-375.
  • Coffin D, Herr C, O'Hara J, Diop S, Hollingsworth R, Srivastava A, Lillicrap D, van den Berg HM, Iorio A, Pierce GF. World bleeding disorders registry: The pilot study. Haemophilia. 2018 May;24(3):e113-e116.
  • Thomas BP, Fouzia NA, Raveendran S, Pallapati SR, Abraham A, Srivastava A. Management of Hemophilic Cysts and Pseudotumors of the Hand in Bleeding Disorders: A Case Series. J Hand Surg Am. 2018 May;43(5):486.e1-486.e9.
  • Timmer MA, Gouw SC, Feldman BM, Zwagemaker A, de Kleijn P, Pisters MF, Schutgens REG, Blanchette V, Srivastava A, David JA, Fischer K, van der Net J. Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia. 2018 Mar;24(2):e33-e49.
  • Abraham AS, Chacko MP, Fouzia NA, Srivastava A, Daniel D. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions. Transfus Med. 2018 Feb 19.
  • George B, Pn N, Devasia AJ, Kulkarni U, Korula A, Lakshmi KM, Abraham A, Srivastava A, Mathews V. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biol Blood Marrow Transplant. 2018 Mar;24(3):494-500.
  • Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Srivastava A, Kaveri SV, Lacroix-Desmazes S. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Cell Immunol. 2018 Mar;325:64-68.
  • Fouzia NA, Edison ES, Lakshmi KM, Korula A, Velayudhan SR, Balasubramanian P, Abraham A, Viswabandya A, George B, Mathews V, Srivastava A. Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned withbusulfan and cyclophosphamide. Bone Marrow Transplant. 2018 Feb;53(2):169-174.
  • Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. J Thromb Haemost. 2018 Feb;16(2):253-261.
  • Korula A, Pn N, Devasia A, Lakshmi KM, Abraham A, Sindhuvi E, George B, Srivastava A, Mathews V. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. Biol Blood Marrow Transplant. 2018 Jan;24(1):103-108.
  • Olson JD, Jennings I, Meijer P, Bon C, Bonar R, Favaloro EJ, Higgins RA, Keeney M, Mammen J, Marlar RA, Meley R, Nair SC, Nichols WL, Raby A, Reverter JC, Srivastava A, Walker I. Lack of grading agreement among international hemostasis external quality assessment programs. Blood Coagul Fibrinolysis. 2018 Jan;29(1):111-119.
  • Oldenburg J, Kulkarni R, Srivastava A, Mahlangu JN, Blanchette VS, Tsao E, Winding B, Dumont J, Jain N. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan;24(1):77-84.
  • Hashmi SK, Srivastava A, Rasheed W, Adil S, Wu T, Jagasia M, Nassar A, Hwang WYK, Hamidieh AA, Greinix HT, Pasquini MC, Apperley JF, Aljurf M. Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):167-172.
  • Ganapule A, Nemani S, Korula A, Lakshmi KM, Abraham A, Srivastava A, Balasubramanian P, George B, Mathews V. Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. J Glob Oncol. 2017 Dec;3(6):773-781.
  • Weisdorf D, Ruiz-Arguelles GJ, Srivastava A, Gómez-Almaguer D, Szer J. Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs? Biol Blood Marrow Transplant. 2017 Nov;23(11):1815- 1816.
  • Korula A, Abraham A, Abubacker FN, Viswabandya A, Lakshmi KM, Abraham OC, Rupali P, Varghese GM, Michael JS, Srivastava A, Mathews V, George B. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country. Mycoses. 2017 Oct;60(10):686-691.
  • Angi M, Kamath V, Yuvarani S, Meena J, Sitaram U, Manipadam MT, Nair S, Ganapule A, Fouzia NA, Abraham A, Viswabandya A, Poonkuzhali B, George B, MathewsV, Srivastava A, Srivastava VM. The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. Hematol Oncol Stem Cell Ther. 2017 Sep;10(3):126-134.
  • Abbas S, Kini A, Srivastava VM, M MT, Nair SC, Abraham A, Mathews V, George B, Kumar S, Venkatraman A, Srivastava A. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Blood Cells Mol Dis. 2017 Jul;66:37-46.
  • Hashmi SK, Srivastava A, Rasheed W, Adil S, Wu T, Jagasia M, Nassar A, Hwang WYK, Hamidieh AA, Greinix HT, Pasquini MC, Apperley JF, Aljurf M. Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematol Oncol Stem Cell Ther. 2017 Jul 14. pii:S1658-3876(17)30055-9.
  • Poonnoose P, Carneiro JDA, Cruickshank AL, El Ekiaby M, Perez Bianco RP, OzeloMC, De Bosch N, Baghaipour M, Tien SL, Chuansumrit A, D'Amico EA, van Zyl A,Sabour A, Candela M, Ricciardi JBS, Ruiz-Sàez A, Ravanbod R, Lam JCL, Jaovisidha S, Kavitha ML, Gibikote S, Shyamkumar N, Srivastava A; MUSFIH Study group.Episodic replacement of clotting factor concentrates does not prevent bleeding ormusculoskeletal damage - the MUSFIH study. Haemophilia. 2017 Jul;23(4):538-546.
  • Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, Abraham A, Viswabandya A, Mathews V, George B, Srivastava A, Balasubramanian P. Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul;52(7):977-983.
  • Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, Abraham A, George B, Srivastava A, Srivastava VM, Mathews V, Balasubramanian P. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol. 2017 Jun;39(3):235-242.
  • Bharathan SP, Nandy K, Palani D, Janet A NB, Natarajan K, George B, Srivastava A, Velayudhan SR. Generation of an induced pluripotent stem cell line that mimics the disease phenotypes from a patient with Fanconi anemia by conditional complementation. Stem Cell Res. 2017 Apr;20:54-57.
  • Bharathan SP, Nandy K, Palani D, Janet A NB, Natarajan K, George B, Srivastava A, Velayudhan SR. Generation of an induced pluripotent stem cell line that mimics the disease phenotypes from a patient with Fanconi anemia by conditional complementation. Stem Cell Res. 2017 Apr;20:54-57.
  • Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM; Wonders Study Investigators. Efficacy and safety of a VWF/FVIII concentrate (Wilate(®) ) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia. 2017 Mar;23(2):264-272.
  • Ganapule A, Jain P, Abubacker FN, Korula A, Abraham A, Mammen J, George B, Mathews V, Srivastava A, Viswabandya A. Surgical procedures in patients with Glanzmann's thrombasthenia: case series and literature review. Blood Coagul Fibrinolysis. 2017 Mar;28(2):171-175.
  • Srivastava A, Shaji RV. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017 Feb;102(2):214-223.
  • Varatharajan S, Abraham A, Karathedath S, Ganesan S, Lakshmi KM, Arthur N, Srivastava VM, George B, Srivastava A, Mathews V, Balasubramanian P. ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. Pharmacogenomics. 2017 Feb;18(3):235-244.
  • Bharathan SP, Manian KV, Aalam SM, Palani D, Deshpande PA, Pratheesh MD, Srivastava A, Velayudhan SR. Systematic evaluation of markers used for the identification of human induced pluripotent stem cells. Biol Open. 2017 Jan 15;6(1):100-108.
  • Fischer K, Poonnoose P, Dunn AL, Babyn P, Manco-Johnson MJ, David JA, van der Net J, Feldman B, Berger K, Carcao M, de Kleijn P, Silva M, Hilliard P, Doria A, Srivastava A, Blanchette V; participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia. 2017 Jan;23(1):11-24.
  • Thangakunam B, Christopher DJ, Mathews V, Srivastava A. Mesenchymal stromal stem cell therapy in advanced interstitial lung disease - Anaphylaxis and short-term follow-up. Lung India. 2015 Sep-Oct;32(5):486-8.
  • Srivastava A, Mason C, Wagena E, Cuende N, Weiss DJ, Horwitz EM, Dominici M. Part 1: Defining unproven cellular therapies. Cytotherapy. 2016 Jan;18(1):117-9.
  • Weiss DJ, Rasko JE, Cuende N, Ruiz MA, Ho HN, Nordon R, Wilton S, Dominici M, Srivastava A. Part 2: Making the "unproven" "proven". Cytotherapy. 2016 Jan;18(1):120-3.
  • Garge S, Keshava SN, Moses V, Mammen S, Ahmed M, Chiramel GK, Cherian V, Manasseh N, George B, Mathews V, Abraham A, Viswabandya A, Srivastava A, Gibikote S. Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. Br J Radiol 2016; 89: 20151064.
  • Varatharajan S, Panetta JC, Abraham A, Karathedath S, Mohanan E, Lakshmi KM,Arthur N, Srivastava VM, Nemani S, George B, Srivastava A, Mathews V,Balasubramanian P. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2016 Nov;78 (5):1051-1058.
  • Srivastava A, van den Berg HM. Standardizing patient outcomes measurement toimprove haemophilia care. Haemophilia. 2016 Sep; 22(5):651-3
  • George L, Peter D, Chopra M, George B, Abraham A, Mathews V, Srivastava A, Pulimood SA. Efficacy of narrow band UVB in the treatment of cutaneous GvHD: an Indian experience. Bone Marrow Transplant. 2016 Jul; 51 (7):988-90.
  • Poonnoose PM, Hilliard P, Doria AS, Keshava SN, Gibikote S, Kavitha ML, Feldman BM, Blanchette V, Srivastava A. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia. 2016 Nov; 22 (6):925-933.
  • Deshpande PA, Srivastava VM, Mani S, Anandhan S, Meena J, Abraham A, Viswabandya A, George B, Srivastava A, Mathews V, Balasubramanian P. Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. Leuk Lymphoma. 2016 Oct;57(10):2481-4.
  • Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua RA, Chomienne C, George B, Balasubramanian P, Mathews V. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2016 Nov; 30(11):2169-2178.
  • Ahmed R, Devasia AJ, Viswabandya A, Lakshmi KM, Abraham A, Karl S, Mathai J, Jacob PM, Abraham D, Srivastava A, Mathews V, George B. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP. Ann Hematol. 2016 Sep;95(9):1429-34.
  • Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2016 May;14(5):1105-9.
  • Carcao M, Srivastava A. Factor VIII/factor IX prophylaxis for severe hemophilia. Seminars in Hematology, 2016 Jan;53(1):3-9.
  • Srivastava A. Current Issues in Hemophilia: Recognizing Clinical Heterogeneity, Replacement Therapy, and Outcome Assessment. Seminars in Thrombosis and hemostasis. 2015;41(8):816.
  • Srivastava A. Inflammation is key to hemophilic arthropathy. Blood. 2015;126(19):2175-6.
  • Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, et al. Acute myeloid leukaemia: challenges and real world data from India. British Journal of haematology. 2015;170(1):110–7.
  • Manian KV, Aalam SMM, Bharathan SP, Srivastava A, Velayudhan SR. Understanding the Molecular Basis of Heterogeneity in Induced Pluripotent Stem Cells. Cellular Reprogramming (Formerly" Cloning and Stem Cells"). 2015;17(6):427-40.
  • Keshava S, Gibikote S, Mohanta A, Poonnoose P, Rayner T, Hilliard P, et al. Ultrasound and magnetic resonance imaging of healthy paediatric ankles and knees: a baseline for comparison with haemophilic joints. Haemophilia. 2015;21(3):e210-e22.
  • George B, Mathews V, Viswabandya A, Abraham A, Ganapule A, Fouzia N, et al. Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia–The CMC Experience. Journal of Association of Physicians of India. 2015;63(3 (Special Issue)):36-40.
  • Doria AS, Keshava SN, Mohanta A, Jarrin J, Blanchette V, Srivastava A, et al. Diagnostic Accuracy of Ultrasound for Assessment of Hemophilic Arthropathy: MRI Correlation. American Journal of Roentgenology. 2015;204(3):W336-47.
  • Dimichele D, Lacroix‐Desmazes S, Peyvandi F, Srivastava A, Rosendaal F. Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2015;13(5):876-9.
  • Blobel CP, Haxaire C, Kalliolias GD, DiCarlo E, Salmon J, Srivastava A. Blood-Induced Arthropathy in Hemophilia: Mechanisms and Heterogeneity. Seminars in Thrombosis and hemostasis. 2015;41(8):832-7.
  • Blanchette VS, Srivastava A. Definitions in Hemophilia: Resolved and Unresolved Issues. Seminars in Thrombosis and hemostasis. 2015;41(8):819-25.
  • Berg H, Feldman B, Fischer K, Blanchette V, Poonnoose P, Srivastava A. Assessments of outcome in haemophilia–what is the added value of QoL tools? Haemophilia. 2015;21(4):430-5.
  • Athiyarath R, Shaktivel K, Abraham V, Singh D, Bondu JD, Chapla A, et al. Association of genetic variants with response to iron supplements in pregnancy. Genes & Nutrition. 2015;10(4):1-8.
  • Athiyarath R, George B, Abraham A, Viswabandya A, Srivastava A, Edison ES. Genetic modifiers of secondary iron overload in beta thalassemia major. Blood Cells, Molecules and Diseases. 2015;3(54):242-3.
  • Arora N, Nair S, Pai R, Nair S, Ahmed R, Abraham A, et al. V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia. Indian Journal of Pathology and Microbiology. 2015;58(1):62.
  • Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics. 2015;16(8):877-90.
  • Srivastava A. Haemophilia care–beyond the treatment guidelines. Haemophilia. 2014;20(s4):4-10.
  • Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, et al. Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of Thrombosis and Haemostasis. 2014;12(11):1788-800.
  • Savoia A, Kunishima S, De Rocco D, Zieger B, Rand ML, Pujol‐Moix N, et al. Spectrum of the Mutations in Bernard–Soulier Syndrome. Human mutation. 2014;35(9):1033-45.
  • Rajagopal V, Sundaresan L, Rajkumar AP, Chittybabu C, Kuruvilla A, Srivastava A, et al. Genetic association between the DRD4 promoter polymorphism and clozapine-induced sialorrhea. Psychiatric genetics. 2014;24(6):273-6.
  • Peyvandi F, Farrugia A, Iorio A, Key N, Srivastava A. Joint WFH‐ISTH session: issues in clinical trial design. Haemophilia. 2014;20(s4):137-44.
  • Mayuranathan T, Rayabaram J, Das R, Arora N, Edison ES, Chandy M, et al. Identification of rare and novel deletions that cause (δβ) 0‐thalassaemia and hereditary persistence of foetal haemoglobin in Indian population. European Journal of haematology. 2014;92(6):514-20.
  • Mathews V, Srivastava A, Chandy M. Allogeneic Stem Cell Transplantation for Thalassemia Major. Hematology/oncology clinics of North America. 2014;28(6):1187-200.
  • Blanchette V, Key N, Ljung L, Manco‐Johnson M, Berg H, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2014;12(11):1935-9.
  • Athiyarath R, George B, Mathews V, Srivastava A, Edison ES. Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia. Annals of hematology. 2014;93(12):2093-5.
  • Abraham A, Karathedath S, Varatharajan S, Markose P, Chendamarai E, Jayavelu AK, et al. ABCB6 RNA expression in leukemias—expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia. Annals of hematology. 2014;93(3):509-12.
  • Abraham A, Karathedath S, Kumaraswamy V, Jayavelu AK, Mani S, Srivastava VM, et al. Novel NPM1 mutation in the 3'-untranslated region identified in two patients with acute myeloid leukemia. Leukemia & lymphoma. 2014;55(6):1421-4.
  • Abraham A, George B, Ahmed R, Viswabandya A, Mathews V, Lakshmi KM, et al. Outcome of treatment with a low cost protocol in adults with T cell acute lymphoblastic leukemia in a tertiary care center in India. Leukemia & lymphoma. 2014;55(4):947-9.
  • Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem cells translational medicine. 2013;2(8):607-13.
  • Sumitha E, Jayandharan G, Arora N, Abraham A, David S, Devi G, et al. Molecular basis of quantitative fibrinogen disorders in 27 patients from India. Haemophilia. 2013;19(4):611-8.
  • Srivastava A, Brewer A, Mauser‐Bunschoten E, Key N, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
  • Shima M, Thachil J, Nair S, Srivastava A. Towards standardization of clot waveform analysis and recommendations for its clinical applications. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2013;11(7):1417-20.
  • Sen I, Stephen E, Agarwal S, Abraham A, Srivastava A. Management of a patient with a true popliteal artery aneurysm, mild hemophilia A and low titre inhibitor. Indian Journal of Thoracic and Cardiovascular Surgery. 2013;29(4):248-9.
  • Sen D, Gadkari RA, Sudha G, Gabriel N, Kumar YS, Selot R, et al. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Human gene therapy methods. 2013;24(2):104-16.
  • Sen D, Chapla A, Walter N, Daniel V, Srivastava A, Jayandharan G. Nuclear factor (NF)‐κB and its associated pathways are major molecular regulators of blood‐induced joint damage in a murine model of hemophilia. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2013;11(2):293-306.
  • Sen D, Balakrishnan B, Gabriel N, Agrawal P, Roshini V, Samuel R, et al. Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Scientific reports. 2013;6.
  • Seidi A, Sampathkumar K, Srivastava A, Ramakrishna S, Ramalingam M. Gradient nanofiber scaffolds for tissue engineering. Journal of nanoscience and nanotechnology. 2013;13(7):4647-55.
  • Rayabaram J, Das R, Arora N, Edison ES, Srivastava A, Velayudhan S. Molecular Basis Of (δβ) 0 Thalassaemia and HPFH In Indian Population and The Role Of Non-Coding Transcripts In Increased Foetal Hemoglobin In Adults. Blood. 2013;122(21):3446-.
  • Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob K. Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatrica. 2013;25(01):2-11.
  • Rajamanickam M, Michael R, Sampath V, John J, Viswabandya A, Srivastava A. Should ice be used in the treatment of acute haemarthrosis in haemophilia? Haemophilia. 2013;19(4):e267-e8.
  • Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A, Sindhuvi E, Lakshmi KM, Srivastava A. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One. 2013 Apr 26;8(4):e61637.
  • Hubbard A, Dodt J, Lee T, Mertens K, Seitz R, Srivastava A, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. Journal of Thrombosis and Haemostasis. 2013;11(5):988-9.
  • Hareendran S, Hussain M, Sen D, Balakrishnan B, SathishKumar Y, Kalaivani V, et al. Bio-Engineering of Adeno-Associated Virus Serotype (AAV)-2 Capsid at Serine/Threonine Residues Improves Its Transduction Efficiency Both In Vitro and In Vivo. Human gene therapy methods. 2013;24(2):80-93.
  • Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR. Adeno‐associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Reviews in medical virology. 2013;23(6):399-413.
  • George B, Mathews V, Lakshmi KM, Melinkeri S, Sharma A, Viswabandya A, et al. The use of a fludarabine‐based conditioning regimen in patients with severe aplastic anemia–a retrospective analysis from three Indian centers. Clinical transplantation. 2013;27(6):923-9.
  • Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biology of Blood and Marrow Transplantation. 2013;19(8):1238-43.
  • Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, et al. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods. 2013;24(2):80-93.
  • Devi GS AN, Rajkumar SV, Edison ES, Srivastava A, Jayandharan GR. Fluorescent PCR-based gene dose analysis for detection of deletion mutations in carriers of haemophilia. Haemophilia. 2013;19(6):e377-80.
  • Desire S, Mohanan EP, George B, Mathews V, Chandy M, Srivastava A, et al. A rapid & sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation. The Indian Journal of medical research. 2013;137(4):777-84.
  • Athiyarath R, Srivastava A, Edison ES. Molecular basis of primary iron overload in India and the role of serum-derived factors in hepcidin regulation. Annals of hematology. 2013;92(6):843-4.
  • Athiyarath R, Arora N, Fuster F, Schwarzenbacher R, Ahmed R, George B, et al. Two novel missense mutations in iron transport protein transferrin causing hypochromic microcytic anaemia and haemosiderosis: molecular characterization and structural implications. British Journal of haematology. 2013;163(3):404-7.
  • Alkindi SS, AlZadjali S, Daar S, Sindhuvi E, Wali Y, Pathare AV, et al. A stepwise α‐thalassemia screening strategy in high‐prevalence areas. European Journal of haematology. 2013;91(2):164-9.
  • Abraham A KS, Varatharajan S, Markose P, Chendamarai E, Jayavelu AK, George B, Srivastava A, Mathews V, Balasubramanian P. ABCB6 RNA expression in leukemias--expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia. Ann Hematol. 2013;93(3):509-12.
  • Viswabandya A BS, Nair SC, Abraham A, George B, Mathews V, Chandy M, Srivastava A. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia. 2012;18(3):e195-200.
  • Varatharajan S, Abraham A, Zhang W, Shaji R, Ahmed R, Abraham A, et al. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. European Journal of clinical pharmacology. 2012;68(12):1577-86.
  • Teoh G, Chen Y, Kim K, Srivastava A, Pai VR, Yoon S-S, et al. Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. 2012;12(2):118-26.
  • Sellathamby S, Lakshmi KM, Busson M, Viswabandya A, George B, Mathews V, et al. Polymorphisms in the Immunoregulatory Genes are Associated with Hematopoietic Recovery and Increased Susceptibility to Bacterial Infections in Patients with Thalassaemia Major Undergoing Matched Related Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2012;18(8):1219-26.
  • Scadden D, Srivastava A. Advancing stem cell biology toward stem cell therapeutics. Cell Stem Cell. 2012;10(2):149-50.
  • Sabapathy V, Ravi S, Srivastava V, Srivastava A, Kumar S. Long-term cultured human term placenta-derived mesenchymal stem cells of maternal origin displays plasticity. Stem cells international. 2012;2012(Article ID 174328):11 pages.
  • Rajkumar A, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob K. Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia. Psychopharmacology. 2012;224(3):441-9.
  • Peyvandi F, Di Michele D, Bolton‐Maggs P, Lee C, Tripodi A, Srivastava A. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. Journal of Thrombosis and Haemostasis. 2012;10(9):1938-43.
  • Peter CD, Chakrapani A, Shah S, Shah A, Srivastava A. Blastic plasmacytoid dendritic cell neoplasm presenting as fever with diffuse cutaneous nodules. Indian Journal of Dermatology. 2012;57(1):45-7.
  • Patkar N, Nair S, Alex AA, Parihar M, Manipadam MT, Arora N, et al. Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India. Leukemia & lymphoma. 2012;53(4):609-15.
  • Patkar N, Alex AA, Ahmed R, Abraham A, George B, Vishwabandya A, et al. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry Part B: Clinical Cytometry. 2012;82(4):252-8.
  • Parihar M, Kumar JA, Sitaram U, Balasubramanian P, Abraham A, Viswabandya A, et al. Cytogenetic analysis of acute myeloid leukemia with t (8; 21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leukemia & lymphoma. 2012;53(1):103-9.
  • Mayuranathan T, Rayabaram J, Edison ES, Srivastava A, Velayudhan SR. A novel deletion of β-globin promoter causing high HbA2 in an Indian population. Haematologica. 2012;97(9):1445-7.
  • Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. Seminars in Thrombosis and hemostasis. 2012;38(1):64-78.
  • Jain PP, Parihar M, Ahmed R, Abraham A, Vishwabandya A, George B, et al. Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis. Indian Journal of Pathology and Microbiology. 2012;55(3):347-51.
  • Gorczyca M, Nair S, Jilma B, Priya S, Male C, Reitter S, et al. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. Journal of Thrombosis and Haemostasis. 2012;10(8):1581-90.
  • Edison E, Sathya M, Rajkumar S, Nair S, Srivastava A, Shaji R. A novel β‐globin gene mutation HBB. c. 22 G> C produces a hemoglobin variant (Hb Vellore) mimicking HbS in HPLC. International Journal of laboratory hematology. 2012;34(5):556-8.
  • De Kleijn P, Odent T, Berntorp E, Hilliard P, Pasta G, Srivastava A, et al. Differences between developed and developing countries in paediatric care in haemophilia. Haemophilia. 2012;18(s4):94-100.
  • David S, Jayandharan GR, Abraham A, Jacob RR, Devi GS, Patkar N, et al. Molecular basis of Wiskott–Aldrich syndrome in patients from India. European Journal of haematology. 2012;89(4):356-60.
  • Dargaud Y, Sorensen B, Shima M, Hayward C, Srivastava A, Negrier C. Global Haemostasis and point of care testing. Haemophilia. 2012;18(s4):81-8.
  • Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, et al. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood. 2012;119(15):3413-9.
  • Balasubramanian P, Desire S, Panetta J, Lakshmi K, Mathews V, George B, et al. Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Bone Marrow Transplantation. 2012;47(9):1178-85.
  • Balasubramanian P, Chendamarai E, Markose P, Fletcher L, Branford S, George B, et al. International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: First report from India. Acta haematologica. 2012;127(3):135-42.
  • Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein Thrombosis: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2012;10(4):698-702.
  • Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics. 2012;13(3):269-82.
  • Sumitha E, Jayandharan G, David S, Jacob R, Sankari Devi G, Bargavi B, et al. Molecular basis of Bernard–Soulier syndrome in 27 patients from India. Journal of Thrombosis and Haemostasis. 2011;9(8):1590-8.
  • Stonebraker JS, BOLTON‐MAGGS PH, Brooker M, Farrugia A, Srivastava A. A study of reported factor IX use around the world. Haemophilia. 2011;17(3):446-55.
  • Padankatti S, Macaden A, Cherian S, Thirumugam M, Pazani D, Kalaiselvan M, et al. A patient‐prioritized ability assessment in haemophilia: the Canadian Occupational Performance Measure. Haemophilia. 2011;17(4):605-11.
  • Nair SC, Viswabandya A, Srivastava A. Diagnosis and management of von Willebrand disease: a developing country perspective. Seminars in Thrombosis and hemostasis. 2011;37(5):587-94.
  • Moorthy RK, Sam GA, Kumar SV, Chacko G, Mathews V, Chacko AG, et al. Intralesional mesenchymal stromal cell transplant in a rodent model of cortical cryoinjury. Neurology India. 2011;59(4):573-8.
  • Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterranean Journal of hematology and infectious diseases. 2011;3(1):e2011056.
  • Manipadam MT, Nair S, Viswabandya A, Mathew L, Srivastava A, Chandy M. Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India. World Journal of Pediatrics. 2011;7(4):318-25.
  • Koumaravelou K, Shoaib Z, Adithan C, Charron D, Srivastava A, Tamouza R, et al. Analysis of human glutathione S-transferase alpha 1 (hGSTA1) gene promoter polymorphism using Denaturing High Performance Liquid Chromatography (DHPLC). Clinica Chimica Acta. 2011;412(15):1465-8.
  • Edison ES, Shaji RV, Chandy M, Srivastava A. Interaction of hemoglobin E with other abnormal hemoglobins. Acta haematologica. 2011;126(4):246-8.
  • Chapla A, Jayandharan GR, Sumitha E, Devi GS, Shenbagapriya P, Nair SC, et al. Molecular basis of hereditary factor V deficiency in India: Identification of four novel mutations and their genotype-phenotype correlation. Thromb Haemost. 2011;105(6):1120-3.
  • Bugalia A, Abraham A, Balasubramanian P, Srivastava A, Nair S. Mast cell sarcoma of the small intestine: a case report. Journal of clinical pathology. 2011;64(11):1035-7.
  • Viswabandya A, Baidya S, Nair SC, Lakshmi KM, Mathews V, George B, et al. Clinical manifestations of combined factor V and VIII deficiency: a series of 37 cases from a single center in India. American Journal of hematology. 2010;85(7):538-9.
  • Taylor PL, Barker RA, Blume KG, Cattaneo E, Colman A, Deng H, et al. Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell. 2010;7(1):43-9.
  • Preston FE LG, Favaloro EJ, Jayandharan GR, Edison ES, Srivastava A. Quality issues in laboratory Haemostasis. Haemophilia. 2010 Jul;16 Suppl 5:93-9.
  • Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of reported factor VIII use around the world. Haemophilia. 2010;16(1):33-46.
  • Rajasekar R, Lakshmi KM, George B, Viswabandya A, Thirugnanam R, Abraham A, et al. Dendritic cell count in the graft predicts relapse in patients with hematologic malignancies undergoing an HLA-matched related allogeneic peripheral blood stem cell transplant. Biology of Blood and Marrow Transplantation. 2010;16(6):854-60.
  • Nair S, Dargaud Y, Chitlur M, Srivastava A. Tests of global Haemostasis and their applications in bleeding disorders. Haemophilia. 2010;16(s5):85-92.
  • Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Journal of Clinical Oncology. 2010;28(24):3866-71.
  • Gupta M, Kumar JA, Sitaram U, Neeraj S, Nancy A, Balasubramanian P, et al. The t (6; 9)(p22; q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer genetics and cytogenetics. 2010;203(2):297-302.
  • George B, Mathews V, Viswabandya A, Lakshmi KM, Srivastava A, Chandy M. Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia—a single-center analysis of 100 patients. Pediatric hematology and oncology. 2010;27(2):122-31.
  • Desire S, Balasubramanian P, Bajel A, George B, Viswabandya A, Mathews V, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Medical Oncology. 2010;27(4):1046-9.
  • Arora N, Nair S, Srivastava A. T/NK-cell post-transplant lymphoproliferative disorder of the urinary bladder: a case report. Journal of Clinical Pathology. 2010;63(11):1042-
  • Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide–based regimen. Biology of Blood and Marrow Transplantation. 2009;15(11):1479-84.
  • Srivastava A. Indian Academy of Neurology: The Dasgupta Oration 2009, Neural regeneration with stem cells: Rebooting the brain. Annals of Indian Academy of Neurology. 2009;12(3):138-9.
  • Rajasekar R, Mathews V, Lakshmi KM, George B, Viswabandya A, Chandy M, et al. Cellular immune reconstitution and its impact on clinical outcome in children with β thalassemia major undergoing a matched related myeloablative allogeneic bone marrow transplant. Biology of Blood and Marrow Transplantation. 2009;15(5):597-609.
  • Pavlova A, Brondke H, Müsebeck J, Pollmann H, Srivastava A, Oldenburg J. Molecular mechanisms underlying hemophilia A phenotype in seven females. Journal of Thrombosis and Haemostasis. 2009;7(6):976-82.
  • Mathews V, Nair SC, David S, Viswabandya A, Srivastava A. Management of hemophilia in patients with inhibitors: the perspective from developing countries. Seminars in Thrombosis and Hemostasis. 2009;35(8):820-6.
  • Mathews V, George B, Lakshmi KM, Viswabandya A, John JM, Sitaram U, et al. Impact of pretransplant splenectomy on patients with β‐thalassemia major undergoing a matched‐related allogeneic stem cell transplantation. Pediatric Transplantation. 2009;13(2):171-6.
  • Mathews V, George B, Lakshmi K, Chendamarai E, Viswabandya A, Srivastava A, et al. Comparison of Clinical Outcomes of Relapsed APL Patients Induced With ATO and Consolidated With Either an Autologous SCT or ATO Based Treatment Regimen. Biology of Blood and Marrow Transplantation. 2009;15(2):36-7.
  • Markose P, Chendamarai E, Balasubramanian P, Velayudhan SR, Srivastava VM, Mathews V, et al. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leukemia & lymphoma. 2009;50(12):2092-5.
  • Jayandharan G, Nair S, Poonnoose P, Thomas R, John J, Keshav S, et al. Polymorphism in factor VII gene modifies phenotype of severe haemophilia. Haemophilia. 2009;15(6):1228-36.
  • George B, Mathews V, Viswabandya A, Srivastava A, Chandy M. Fludarabine‐based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections. Clinical Transplantation. 2009;23(2):228-32.
  • Edison ES, Athiyarath R, Rajasekar T, Westerman M, Srivastava A, Chandy M. A novel splice site mutation c. 2278 (− 1) G> C in the TMPRSS6 gene causes deletion of the substrate binding site of the serine protease resulting in refractory iron deficiency anaemia. British Journal of Haematology. 2009;147(5):766-9.
  • Viswabandya A MV, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A. Successful surgical Haemostasis in patients with von Willebrand disease with Koate (R) DVI. Haemophilia. 2008;14(4):763-7.
  • Vassord C, Lapouméroulie C, Koumaravelou K, Srivastava A, Krishnamoorthy R. Endothelial cells do not express GSTA1: potential relevance to busulfan‐mediated endothelial damage during haematopoietic stem cell transplantation. European Journal of Haematology. 2008;80(4):299-302.
  • Srivastava A, Hoots W, Soucie J, Ludlam C. Linking the world with training and research for improving haemophilia care. Haemophilia. 2008;14(s3):43-8.
  • Rodeghiero F, RUIZ‐SÁEZ A, BOLTON‐MAGGS P, Hayward C, Nair S, Srivastava A. Laboratory issues in bleeding disorders. Haemophilia. 2008;14(s3):93-103.
  • Rajasekar R, Mathews V, Lakshmi KM, Sellathamby S, George B, Viswabandya A, et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biology of Blood and Marrow Transplantation. 2008;14(3):344-50.
  • Ponder K, Srivastava A. Walk a mile in the moccasins of people with haemophilia. Haemophilia. 2008;14(3):618-20.
  • Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Seminars in Thrombosis and Hemostasis. 2008;34(1):128-41.
  • Hyun I, Lindvall O, Ährlund-Richter L, Cattaneo E, Cavazzana-Calvo M, Cossu G, et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell. 2008;3(6):607-9.
  • George B, Mathews V, Viswabandya A, Kavitha M, Srivastava A, Chandy M. Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. Pediatric Transplantation. 2008;12(1):14-9.
  • Edison E, Shaji R, Devi S, Moses A, Viswabandhya A, Mathews V, et al. Analysis of β globin mutations in the Indian population: presence of rare and novel mutations and region‐wise heterogeneity. Clinical Genetics. 2008;73(4):331-7.
  • Bajel A, George B, Mathews V, Viswabandya A, Kavitha M, Srivastava A, et al. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatric Blood & Cancer. 2008;51(5):621-5.
  • Subramaniam K, George B, Mathews V, Viswabandya A, Srivastava A, Chandy M. Salvage with a mini-allograft after primary engraftment failure following autologous transplant for multiple myeloma. Bone Marrow Transplantation. 2007;39(4):239-40.
  • Poonnoose P, Thomas R, Keshava S, Cherian R, Padankatti S, Pazani D, et al. Psychometric analysis of the functional independence score in haemophilia (FISH). Haemophilia. 2007;13(5):620-6.
  • Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92(7):994-5.
  • Mathews V, George B, Viswabandya A, Lakshmi K, Chandy M, Srivastava A. 11: Impact of pre-transplant splenectomy on patients with β thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2007;13(2 Supplement):6.
  • Mathews V, George B, Deotare U, Lakshmi KM, Viswabandya A, Daniel D, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with β thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2007;13(8):889-94.
  • Manipadam M, Viswabandya A, Srivastava A. Primary splenic marginal zone lymphoma with florid granulomatous reaction—A case report and review of literature. Pathology-Research and Practice. 2007;203(4):239-43.
  • Mammen J, Nair SC, Srivastava A. External quality assessment scheme for hemostasis in India. Seminars in Thrombosis and Hemostasis. 2007;33(3):265-72.
  • Lee V, Srivastava A, Nithyananth M, Kumar P, Cherian V, Viswabandya A, et al. Fracture neck of femur in haemophilia A–experience from a cohort of 11 patients from a tertiary centre in India. Haemophilia. 2007;13(4):391-4.
  • Jayandharan GR, Viswabandya A, Nair SC, Chandy M, Srivastava A. Molecular basis of hereditary factor VII deficiency in India: five novel mutations including a double missense mutation (Ala191Glu; Trp364Cys) in 11 unrelated patients. Haematologica. 2007;92(7):1002-3.
  • Jayandharan G SM, Viswabnadya A, Chandy M, Srivastava A, Peyvandi F. Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India. Haemophilia. 2007;13(4):413-9.
  • Jayandharan G, Nelson E, Baidya S, Chandy M, Srivastava A. A new multiplex PCR and conformation‐sensitive gel electrophoresis strategy for mutation detection in the platelet glycoprotein αIIb and β3 genes. Journal of Thrombosis and Haemostasis. 2007;5(1):206-9.
  • George B, Mathews V, Viswabandya A, Kavitha M, Srivastava A, Chandy M. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplantation. 2007;40(1):13-8.
  • Feldman BM AL, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, LundinB, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W, Blanchette VS. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the second international prophylaxis study group (ipsg) symposium. Haemophilia. 2007;13(6):745–9.
  • Feldman B, Aledort L, Bullinger M, Delaney F, Doria A, Funk S, et al. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia. 2007;13(6):745-9.
  • Bajel A, George B, Mathews V, Viswabandya A, Kavitha M, Srivastava A, et al. Adult ALL: treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol. Leukemia. 2007;21(10):2230-3.
  • Srivastava A. Uncertain times for research on hemophilia and allied disorders. Journal of Thrombosis and Haemostasis. 2006;4(3):680.
  • Srivastava A. Stem cell research in India: from hype and hope to reality. Natl Med J India. 2006 Sep-Oct;19(5):243-5.
  • Sellathamby S, Balasubramanian P, Sivalingam S, Shaji R, Mathews V, George B, et al. Developing an algorithm of informative markers for evaluation of chimerism after allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2006;37(8):751-5.
  • Sadler J, Budde U, Eikenboom J, Favaloro E, Hill F, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis and Haemostasis. 2006;4(10):2103-14.
  • Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study. Journal of Thrombosis and Haemostasis. 2005 Dec;3(12):2619-26.
  • Poonnoose PM, Srivastava A. Functional assessment of arthropathy—an international perspective. Seminars in Hematology. 2006;43:S27-S32.
  • Peyvandi F JG, Chandy M, Srivastava A, Nakaya SM, Johnson MJ,Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia. 2006;6(Supplement s3):82–9.
  • Peretz H, Rosenberg N, Landau M, Usher S, Nelson E, Mor-Cohen R, et al. Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of aIIbb3 integrin (ITGA2B, ITGB3). Human Mutation. 2006;27(4):359-69.
  • Nelson E, Nair S, Peretz H, Coller B, Seligsohn U, Chandy M, et al. Diversity of Glanzmann thrombasthenia in southern India: 10 novel mutations identified among 15 unrelated patients. Journal of Thrombosis and Haemostasis. 2006;4(8):1730-7.
  • Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627-32.
  • Mathews V, George B, Lakshmi K, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood. 2006;107(7):2627-32.
  • Mathews V, Desire S, George B, Lakshmi K, Rao J, Viswabandya A, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006;20(5):881-3.
  • Lillicrap D, Nair S, Srivastava A, Rodeghiero F, Pabinger I, Federici A. Laboratory issues in bleeding disorders. Haemophilia. 2006;12(s3):68-75.
  • Jayandharan GR, Viswabandya A, Baidya S, Nair SC, George B, Mathews V, et al. Mutations in coagulation factor XIII A gene in eight unrelated Indians Five novel mutations identified by a novel PCR-CSGE approach. Thromb Haemost. 2006;95(3):551-6.
  • Hertzberg M, Mammen J, McCraw A, Nair S, Srivastava A. Achieving and maintaining quality in the laboratory. Haemophilia. 2006;12(s3):61-7.
  • George B, Mathews V, Viswabandya A, Srivastava A, Chandy M. Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatric Transplantation. 2006;10(1):48-54.
  • Deotare U, Vishwabandya A, Mathews V, George B, Srivastava A, Chandy M. Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation. Bone Marrow Transplantation. 2006;37(12):1149-50.
  • Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom J, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. Journal of Thrombosis And Haemostasis. 2006;4(10):2164-9.
  • Beeton K, De Kleijn P, Hilliard P, Funk S, Zourikian N, Bergstrom BM, et al. Recent developments in clinimetric instruments. Haemophilia. 2006;12(s3):102-7.
  • Srivastava A, You SK, Ayob Y, Chuansumrit A, de Bosch N, Perez Bianco R, et al. Hemophilia treatment in developing countries: products and protocols. Seminars in Thrombosis and Hemostasis. 2005;31(5):495-500.
  • Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Seminars in Thrombosis and Hemostasis. 2005;31(5):569-76.
  • Srivastava A. Optimizing clotting factor replacement therapy in hemophilia: A global need. Hematology. 2005;10(Supplement-1):229-30.
  • Srivastava A. Gene therapy for hemophilia? Journal of Thrombosis and Haemostasis. 2005;3(6):1313-.
  • Srivastava A. von Willebrand disease in the developing world. Seminars in Hematology. 2005;42(1):36-41.
  • Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis. 2005;3(12):2619-26.
  • Poonnoose P, Manigandan C, Thomas R, Shyamkumar N, Kavitha M, Bhattacharji S, et al. Functional Independence Score in Haemophilia: a new performance‐based instrument to measure disability. Haemophilia. 2005;11(6):598-602.
  • Poonkuzhali B, Shaji R, Salamun D, George B, Srivastava A, Chandy M. Cytochrome P4501A1 and glutathione S transferase gene polymorphisms in patients with aplastic anemia in India. Acta Haematologica. 2005;114(3):127-32.
  • Mathews V, Viswabandya A, Baidya S, George B, Nair S, Chandy M, et al. Surgery for hemophilia in developing countries. Seminars in Thrombosis and Hemostasis. 2005;31(5):538-43.
  • Jayandharan GR, Shaji RV, Baidya S, Nair SC, Chandy M, Srivastava A. Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India. Thromb Haemost. 2005;94(4):883-6.
  • Jayandharan G VA, Baidya S, Nair SC, Shaji RV, Chandy M, Srivastava A. Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 --> Thr (Prothrombin Vellore 1) mutation. J Thromb Haemost. 2005;3(7):1446-53.
  • Jayandharan G VA, Baidya S, Nair SC, Shaji RV, George B, Chandy M, Srivastava A. Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin. J Thromb Haemost. 2005;3(7):1482-7.
  • Jayandharan G SR, Baidya S, Nair SC, Chandy M, Srivastava A. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia. 2005;11(5):481-91.
  • George B, Poonkuzhali B, Srivastava V, Chandy M, Srivastava A. Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARα acute promyelocytic leukemia (APML). Annals of hematology. 2005;84(6):406-8.
  • George B, Mathews V, Viswabandhya A, Kavitha N, Srivastava A, Chandy M. Acute and chronic graft-versus-host disease (GVHD) in patients undergoing allogeneic BMT for thalassaemia major. Biology of Blood and Marrow Transplantation. 2005;11(2):9-10.
  • George B, Mathews V, Shaji R, Srivastava V, Srivastava A, Chandy M. Fludarabine-based conditioning for allogeneic stem cell transplantation for multiply transfused patients with Fanconi's anemia. Bone Marrow Transplantation. 2005;35(4):341-3.
  • G. Jayandharan, Shaji RV, S.C. Nair, M. Chandy, Srivastava A. Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val). Thromb Haemost. 2005;3(4):808–11.
  • Edison ES, Shaji RV, Srivastava A, Chandy M. Hyperbilirubinemia in homozygous HbE disease is associated with the UGT1A1 gene polymorphism. Hemoglobin. 2005;29(3):189-95.
  • Edison ES, Shaji RV, Srivastava A, Chandy M. Compound heterozygosity for Hb E and Hb Lepore-Hollandia in India; first report and potential diagnostic pitfalls. Hemoglobin. 2005;29(3):221-4.
  • Edison ES, Shaji RV, Devi SG, Kumar SS, Srivastava A, Chandy M. Hb Showa-Yakushiji [β110 (G12) Leu→ Pro] in four unrelated patients from west Bengal. Hemoglobin. 2005;29(1):19-25.
  • E.J.R. Nelson JL, W.B. Mitchell, M. Chandy, A.Srivastava, B.S. Coller. Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. J Thromb Haemost. 2005;3(12):2773-83.
  • Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults–a report on 90 patients. European Journal of Haematology. 2005;75(4):328-31.
  • Damodar S, George B, Mammen J, Mathews V, Srivastava A, Chandy M. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants. Bone Marrow Transplantation. 2005;36(3):233-5.
  • Chandy M BP, Shaji R V, Mathews V, George B, Dennison D, Krishnamoorthy R, Srivastava A. Randomized trial of two different conditioning regimes for BMT in thalassaemia – The role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant. 2005;36(10):839-45.
  • Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104(5):1574-7.
  • Srivastava A. Dose and response in haemophilia–optimization of factor replacement therapy. British Journal of Haematology. 2004;127(1):12-25.
  • Jayandharan G SR, George B, Chandy M, Srivasatva A. Informativeness of linkage analysis for genetic diagnosis of haemophilia A in India. Haemophilia. 2004;10(5):553-9.
  • George B MV, Srivastava A, Chandy M. Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant. 2004;33(3):311-5.
  • George B, Mathews V, Poonkuzhali B, Shaji R, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18(10):1587-90.
  • George B, Mathews L, Balasubramanian P, Shaji RV, Srivastava A, Chandy M. Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia. Haematologica. 2004;89(10):1266-7.
  • Fischer K, Van den Berg H, Thomas R, Kumar S, Poonnoose P, Viswabandya A, et al. Dose and outcome of care in haemophilia–how do we define cost‐effectiveness? Haemophilia. 2004;10(s4):216-20.
  • Evatt B, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. Haemophilia. 2004;10(s4):9-13.
  • Srivastava A, Usher S, Nelson EJ, Jayandharan G, Shaji RV, Chandy M, et al. Prenatal diagnosis of Glanzmann thrombasthenia. National Medical Journal of India. 2003;16(4):207-8.
  • Srivastava A. Factor replacement therapy in haemophilia–are there models for developing countries? Haemophilia. 2003;9(4):391-6.
  • Shaji RV, Edison ES, Krishnamoorthy R, Chandy M, Srivastava A. Hb Lepore in the Indian population. Hemoglobin. 2003;27(1):7-14.
  • Shaji R, Eunice S, Baidya S, Srivastava A, Chandy M. Determination of the breakpoint and molecular diagnosis of a common α‐thalassaemia‐1 deletion in the Indian population. British Journal of Haematology. 2003;123(5):942-7.
  • Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells, Molecules, and Diseases. 2003;30(3):264-70.
  • Srivastava A, Mathews V, Bhurani D, Baidya S, Chandy M. Successful surgical hemostasis in patients with von Willebrand disease following infusion of KoateDVI. Thrombosis and Haemostasis. 2002;87(3):541-3.
  • Shivakumar S, Poonkhuzhali B, Gunasekaran S, Srivastava A, Chandy M. Cytogenetic, fluorescent in situ hybridization & reverse transcriptase-polymerase chain reaction analysis in acute promyelocytic leukaemia patients. Indian Journal of Medical Research. 2002;115:59.
  • Shivakumar S, Mathew S, Dalton J, Chandy M, Srivastava A. A complex karyotype involving chromosomes 3, 6, 11, 12, and 22 in adult acute lymphoblastic leukemia. Leukemia & Lymphoma. 2002;43(8):1673-7.
  • Shaji RV, Srivastava A, Krishnamoorthy R, Chandy M. Coexistence of a novel β-globin gene deletion (codons 81–87) with the codon 30 (g→ c) mutation in an indian patient with β0-thalassemia. Hemoglobin. 2002;26(3):237-43.
  • Shaji RV, Gerard N, Krishnamoorthy R, Srivastava A, Chandy M. A novel β-thalassemia mutation in an Asian Indian. Hemoglobin. 2002;26(1):49-57.
  • Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. American Journal of Hematology/Oncology. 2002;70(4):292-9.
  • Kang G, Srivastava A, Pulimood AB, Dennison D, Chandy M. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in South India1. Transplantation. 2002;73(8):1247-51.
  • Srivastava A, Mathews V. Hairy cell leukaemia--therapeutic options. The Journal of the Association of Physicians of India. 2001;49:783-4.
  • Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia. 2001;7(1):117-22.
  • Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug metabolism and disposition. 2001;29(3):264-7.
  • Mathews V, Chandy M, Srivastava A. Arsenic trioxide in the management of acute promyelocytic leukaemia. National Medical Journal Of India. 2001;14(4):215-22.
  • Mathews V, Balasubramanian P, RV S, George B, Chandy M, Srivastava A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri‐oxide. British Journal of Haematology. 2001;113(1):257-8.
  • George B MV, Srivastava V, Srivastava A, Chandy M. Tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant. 2001;27(9):973-5.
  • George B, Danda D, Chandy M, Srivastava A, Mathews V. Polymyositis–an unusual manifestation of chronic graft-versus-host disease. Rheumatology International. 2001;20(4):169-70.
  • Finny GJ MV, Abraham P, Abraham M, Chandy M, Srivastava A, Nitsche A, Siegert W, Sridharan G. A pilot study on the role of cytomegalovirus & human herpesvirus-6 infections in Indian bone marrow transplant recipients. Indian J Med Res. 2001;114:39-46.
  • Chandy M SA, Dennison D, Mathews V, George B. Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant. 2001;10(5):553-9.
  • Balasubramanian P CM, Krishnamoorthy R, Srivastava A. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28(9):821-5.
  • Balasubramanian P, Srivastava A, Chandy M. Stability of busulfan in frozen plasma and whole blood samples. Clinical chemistry. 2001;47(4):766-8.
  • Mathews V, Srivastava A, Nair SC, Chandy M. Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease. Natl Med J India. 2000;13:188-90.
  • Singh S, Cherian R, George B, Nair S, Srivastava A. Unusual extra‐axial central nervous system involvement of non‐Hodgkin’s lymphoma: Magnetic resonance imaging. Australasian Radiology. 2000;44(1):112-4.
  • Sadler J, Mannucci P, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, Diagnosis and Treatment of von Willebrand Disease*. Thromb Haemost. 2000;84(2):160-74.
  • Lalitha M, Pai R, Manoharan A, Jesudason M, Brahmadathan K, Srivastava A, et al. Systemic bacterial infections in bone marrow transplant patients. Indian Journal of Cancer. 2000;37(1):10-4.
  • Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost. 2000;84(4):536-40.
  • Srivastava A, Nair S, Srivastava V, Balamurugan A, Jeyaseelan L, Chandy M, et al. Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis. Bone Marrow Transplantation. 1999;23(5):463-7.
  • Mathew LG, Chandy M, Dennison D, Srivastava A, Ganapathy K, Cherian T. Successful bone marrow transplantation in an infant with Wiskott-Aldrich syndrome. Indian Pediatr. 1999 Jul;36(7):707-10.
  • Srivastava A. Factor replacement for haemophilia--should cryoprecipitate be used? Haemophilia: the official Journal of the World Federation of Hemophilia. 1999;5(5):301-5.
  • Quernin M-H, Poonkuzhali B, Médard Y, Dennison D, Srivastava A, Krishnamoorthy R, et al. High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. Journal of Chromatography B: Biomedical Sciences and Applications. 1999;721(1):147-52.
  • Poonkuzhali B, Srivastava A, Quernin M, Dennison D, Aigrain E, Kanagasabapathy A, et al. CONDITIONING REGIMENS-Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation. 1999;24(1):5-12.
  • Poonkuzhali B, Srivastava A, Quernin M, Dennison D, Aigrain E, Kanagasabapathy A, et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation. 1999;24(1):5-11.
  • Mathew L, Chandy M, Dennison D, Srivastava A, Ganapathy K, Cherian T. Successful bone marrow transplantation in an infant with Wiskott-Aldrich syndrome. Indian Pediatrics. 1999;36(7):707.
  • Srivastava A CM, Sunderaj GD, Lee V, Daniel AJ, Dennison D, Nair SC, Matthews V, Anderson G, Nair A, Moses BV, Sudarsanam A. Low dose intermittent factor replacement for post-operative Haemostasis in haemophilia. Haemophilia. 1998;4(6):799-801.
  • Srivastava A. Delivery of haemophilia care in the developing world. Haemophilia. 1998;4(s2):33-40.
  • Quernin M-H, Poonkuzhali B, Montes C, Krishnamoorthy R, Dennison D, Srivastava A, et al. Quantification of busulfan in plasma by gas chromatography–mass spectrometry following derivatization with tetrafluorothiophenol. Journal of Chromatography B: Biomedical Sciences and Applications. 1998;709(1):47-56.
  • Lee C, Kessler C, Varon D, Martinowitz U, Heim M, Srivastava A, et al. Management of haemophilia in the developing world. Haemophilia. 1998;4(4):474-80.
  • Lee C, Kessler C, Varon D, Martinowitz U, Heim M, BIRD A, et al. Factor concentrates for haemophilia in the developing world. Haemophilia. 1998;4(4):481-5.
  • Sahu S, Shah SS, Srivastava A, Dennison D, Chandy M. Ediatric Hyperfibrotic Myelodysplasia: An Unusual Clinicopathologic Entity. Pediatric Hematology-Oncology. 1997;14(2):133-9.
  • Jones S.P SA, Dennison D, Mathews M.S. Evaluation of lysis centrifugation method in the detection of fungemia. Ind J Med Microbiol. 1997;15(2):72.
  • Thomas S, Srivastava A, Jeyaseelan L, Dennison D, Chandy M. NESTROFT as a screening test for the detection of thalassaemia & common haemoglobinopathies--an evaluation against a high performance liquid chromatographic method. The Indian Journal of Medical Research. 1996;104:194-7.
  • Srivastava VM, Krishnaswami H, Srivastava A, Dennison D, Chandy M. Infections in haematological malignancies: an autopsy study of 72 cases. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1996;90(4):406-8.
  • Dabadhghao S, Srivastava A, Dennison D. Bilateral submandibular salivary gland enlargement during chemotherapy for acute myeloid leukaemia. Acta Haem. 1996;96(2):112.
  • Srivastava A, Gottlieb D,, Bradstock KF. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15(6):863-7.
  • Poonkuzhali B, Victoria J, Selvakumar R, Dennison D, Srivastava A, Jeyaseelan L, et al. Comparison of HPLC & EMIT methods of cyclosporine assay in blood after bone marrow transplantation. The Indian Journal of Medical Research. 1995;102:39-41.
  • Muralitharan S, Srivastava A, Shaji R, Mathai M, Srivastava V, Dennison D, et al. Prenatal diagnosis of beta-thalassaemia mutations using the reverse dot blot technique. The National medical Journal of India. 1995;9(2):70-1.
  • Bhave AA, Srivastava A, Lee V, Daniel AJ, Dennison D, Sunderaj GD, Sudarsanam A. Low dose activated factor IX complex concentrate (FEIBAR) for post-operative Haemostasis in a patient with high responding factor VIII inhibitor. Haemophilia. 1995;1(4):274-6.
  • Ramani P, Krishnaswami H, Srivastava A, Dennison D, Chandy M. Infections in bone marrow transplant recipients in south India--a post-mortem study. The Journal of tropical medicine and hygiene. 1994;97(6):354-6.
  • Kudva GC, Chandy M, Dennison D, Srivastava A, Bhushan V. Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen. Indian Journal of Cancer. 1994;31(1):1-7.
  • Kudva G, Chandy M, Raghupathy P, Dennison D, Srivastava A, Bhushan V, et al. Treatment of childhood acute lymphoblastic leukaemia with the BFM regimen. Indian Journal of Cancer. 1994;31(2):78-85.
  • Bhushan V, Chandy M, Khanduri U, Dennison D, Srivastava A, Apte S. Surgery in patients with congenital coagulation disorders. National Medical Journal of India. 1994;7:8-12.
  • Bhushan V, Chandy M, Babu P, Dennison D, Srivastava A, Saraswathi N, et al. Transfusion associated HIV infection in patients with haematologic disorders in southern India. The Indian Journal of Medical Research. 1994;99:57-60.
  • Srivastava A PH, Coultis N, Jindra J, Bryant J, Wylie B. Removal of HLA class I antigens from platelet surface using acidified chloroquine. Vox Sang. 1993;65:146-50.
  • Srivastava A BK, Szer J, DiBortoli L, Gottlieb D. Busulfan and melphalan as a conditioning regimen for bone marrow transplantation. Bone Marrow Transplant. 1993;12:323-9.
  • Dennison D, Vaughan W, Chandy M, Srivastava A, Pulimood B. Bone marrow transplantation in India: appropriate or inappropriate technology. Int third world studies J Rev. 1990;2:1-5.
  • Srivastava A, Cherian A. Recent trends in the chemotherapy of tuberculosis. Indian Journal of medical sciences. 1987;41(1):17-9.
  • Srivastava A CR, John L. Isolated gingival tuberculosis. Ind J Chest Dis All Sci. 1986;3:166-8.
  • Srivastava A, Joseph AG, Cherian A. Felty's Syndrome in an Asian. Rheumatology. 1985;24(3):303.
  • Lalitha M, Anandi V, Srivastava A, Thomas K, Cherian A, Chandi S. Isolation of Acanthamoeba culbertsoni from a patient with meningitis. Journal of clinical microbiology. 1985;21(4):666-7.

Education And Training

Duration Institution Particulars Of Training
1976-1982 Christian Medical College, Vellore Undergraduate education in Medicine
1983-1986 Christian Medical College, Vellore Postgraduate training in General Medicine
1987-1989 Christian Medical College, Vellore Sub-specialty experience in Haematology
1990-1993 Inst of Clin Path & Med Res Westmead Centre,
Sydney, Australia 		Training in Haematology
(Clinical & Laboratory)
1991(Apr-Jul) Red Cross Blood Trans Service
Sydney, Australia 		Transfusion Medicine

Professional Qualifications

Degree University / College Subject Year
MBBS University of Madras, India MEDICINE 1983
MD University of Madras, India GENERAL MEDICINE 1987
FRACP Royal Australasian College of Physicians INTERNAL MEDICINE
(Subspecialty – Haematology) 		1993
FRCPA Royal Australasian College of Physicians HAEMATOLOGY 1993
FRCP (Hon) Royal College of Physicians, UK HAEMATOLOGY 2004

Current Positions

  • Professor of Medicine, Department of Haematology, Christian Medical College, Vellore, India
  • Head, Center for Stem Cell Research, Christian Medical College, Vellore, India
  • Co-chair, Scientific & Technical Appraisal Group, Dept. of Biotech.(DBT), Govt. of India
  • Chair, Genome Engineering Technologies & Applications Committee, DBT, Govt. of India
  • Vice-Chair, Asia Pacific Blood and Marrow Transplantation Group
  • Co-Chair, Gene Therapy Working Group, FVIII/IX subcommittee of SSC, ISTH
  • Chair, WFH Guidelines for Management of Hemophilia Writing Group
  • Chair, Asia Pacific Hemophilia Working Group

Past Positions

  • Head, Department of Haematology, Christian Medical College, Vellore, India (2006-2014)
  • Chair, National Apex Comm., Stem Cell Res. & Therapy, DHR, MOH, Govt. of India (2010-2016)
  • Ida Scudder Research Chair, Christian Medical College, Vellore (2012-2016)
  • Vice President, Medical, World Federation of Hemophilia (2012-2014)
  • Vice-Chair, Center for International Blood and Marrow Transplantation Research (2011-2014)
  • Vice President, Communications and Public Policy, World Federation of Hemophilia (2010-12)
  • Chair, International Ext. Quality Assessment Scheme, World Fed. of Hemophilia (2008 – 2012)
  • Co-Chair, Taskforce on Stem Cell Research and Reg. Med., DBT, Govt. of India (2006-2012)
  • Co-Chair, Clinical Translation Committee, ISSCR (2008-2011)
  • Co-chair, FVIII/IX subcommittee, SSC of ISTH (2001-2006)
  • Chair, FVIII/IX subcommittee, SSC of ISTH (2006-2010)

Academic Appoinments

1987-1992 Assistant Professor Department of Haematology
1992-1996 Associate Professor Christian Medical College, Vellore
1996 onwards Professor Tamil Nadu Dr. MGR Medical University, Chennai, India

Honours Received

  • 2002 :Rev. Fr. Lourdu M. Yeddanapalli Gold Medal for the best researcher, Christian Medical College, Vellore
  • 2004: Manorma Sapre Oration – Indian Society of Hematology and Blood Transfusion
  • 2006: Henri Chaigneau Medal – XVIth International prize of the French Association of Haemophiliacs
  • 2007: J G Parikh Oration – Indian Society of Haematology and Transfusion Medicine
  • 2009: L R Sarin Oration – SMS Medical College, Jaipur, Rajastahan.
  • 2009: Das Gupta Oration – Indian Academy of Neurology
  • 2010: Pia Glas Greenwalt Memorial Lecture – International Society on Thrombosis and Haemostasis
  • 2012 : Ramalingaswamy Oration – Institute of Liver and Biliary Sciences, New Delhi
  • 2012 : Inga Marie Nilsson Award – World Federation of Hemophilia, Montreal, Canada
  • 2012:Ida Scudder Research Chair, Christian Medical College, Vellore (on going).
  • 2016 :Malathi Sathe Oration of the Indian Society of Haematology & Blood Transfusion

Membership of Professional Bodies

  • Indian Society of Haematology and Blood Transfusion
  • International Society on Thrombosis Haemostasis
  • American Society of Hematology
  • International Society for Stem Cell Research
  • International Society of Experimental Hematology
  • American Society for Cell and Gene Therapy

World Health Organization Assignments

  • Haemophilia care in the developing world – June,1997 Represented developing countries in this joint WHO / WFH meeting
  • Impact, prevention and control of von Willebrand disease – October, 1998 Represented developing countries in this joint WHO / ISTH meeting
  • Delivery of Haemophilia Treatment – February, 2002. Represented developing countries in this joint WHO / WFH meeting

Editorial Positions

  • Associate Editor, Seminars in Thrombosis and Hemostasis
  • Associate Editor, Frontiers in Alloimmunity and Transplantation
  • Member, Editorial Board of HAEMOPHILIA
  • Member, Editorial Board, Journal of Thrombosis and Hemostasis
  • Member, Editorial Board, Blood Coagulation and Fibrinolysis

Guest Editorial Work

1. Seminars in Thrombosis and Hemostasis.

Guest editor for “Diagnosis and management of Hemophilia and von Willebrand disease in developing countries”, 2005; 31(5).

Guest Editor for special issue on “Management of Hemophilia” (2015)

2. Association of Physicians of India - Textbook of Medicine,

Section Editor for Haematology:

VIIth Edition, 2002,

VIIIth Edition, 2007,

XIth Edition, 2018,

PhD Doctoral Thesis Guided

  • 2008 : Jayandharan G R, Tamil Nadu Medical University: Exploring the genetics of severe haemophilia and the basis of its phenotypic heterogeneity
  • 2010 : Shanmugaapriya S, Tamil Nadu Medical University: Genetic Determinants of Outcome in Allogeneic Bone Marrow Transplantation
  • 2011 : Reena Rajasekhar, Tamil Nadu Medical University: Study of graft characteristics and immune reconstitution after allogeneic HSCT and their impact on outcome.
  • 2014 : Selva Titus Chacko, Tamil Nadu Medical University: Assessment and Prevention of Health Care Associated Infections in Patients with Hematological Disorders
  • 2014 : Nishant Gabriel, Tamil Nadu Medical University: Effect of Notch Signalling on human mesenchymal stromal cells homeostasis and differentiation
  • 2015 : Nancy Arthur, Tamil Nadu Medical University: Molecular basis of Fanconi anemia in Indian Population
  • 2015 : Sangeetha H, Sree Chitra Tirunal Institute of Medical Sciences University: Strategies to Evade Immune Response Against Adeno-Associated Virus Vectors During Gene Therapy
  • 2015 : Abbas Salar, Sree Chitra Tirunal Institute of Medical Sciences University: The Hematopoietic Stem cell Niche in bone marrow failure syndromes
  • 2015 : Sumitha E, Sree Chitra Tirunal Institute of Medical Sciences University: Molecular Genetics of Von Willebrand Disease
  • 2019 : Salar Abbas, Sree Chitra Tirunal Institute of Medical Sciences University: Evaluating the Bone Marrow Hematopoietic Stem Cell Niche in Bone Marrow Failure Syndromes and Malignancies

Patents

  • Production of a recombinant factor VIII in CHO cells lines (Ref.: 3777/CHE/2012 and PCT/IB2013/058449)
  • Expression of individual chains of factor VIII in Pichia pastoris followed by their functional reconstitution (Ref.: 3778/CHE/2012 and PCT/IB2013/058490)

Department of Haematology

Christian Medical College
Vellore - 632004, India

Phone : +91 416 2282352 / 2282472

Fax: +91 416 2226449 / 2232035

E-Mail: aloks@cmcvellore.ac.in



Centre for Stem Cell Research

Christian Medical College
Bagayam, Vellore-632002, India

Phone : +91-416-2284101 / 2284102

Fax: +91-416-2284103 / 2226449

E-Mail: cscr@cmcvellore.ac.in

Copyright 2019 @ Department of Haematology